Early Outcome in Unstable Angina Patients With Low EF After CABG

Early Outcome in Chronic Unstable Angina Patients With Low Ejection Fraction After CABG

Coronary artery bypass grafting (CABG) among patients with reduced myocardial function remains a surgical challenge despite improvement in surgical technique, myocardial protection and postoperative care. Such cases are considered as high risk and associated with a higher peri-operative mortality than those with normal left ventricular function (LVF). Patients with low EF are at higher risks of sudden death, ventricular arrhythmia, and worsening heart failure due to recurrent ischemia. Therefore,early recognition of patients at risk for a worse outcome plays a pivotal role in the decision making process, allowing the prompt institution of an adequate support.

Study Overview

• Status: Unknown
• Conditions: CABG in Low EF
• Intervention / Treatment: Procedure: CABG

Detailed Description

Current treatment options for Chronic Unstable Angina patients with low Ejection Fraction include intensive medical therapy, surgical revascularization, ventricular remodeling, and heart transplantation. Medical treatment alone is problematic because of limited long-term survival. Heart transplantation offers excellent results with a 65.6 % 5-year survival rate; however, the scarcity of donor organs, the need for lifelong immunosuppression and the fact that heart transplantation has been restricted to those without co-morbid medical conditions and relatively restricted to those younger than 65 years of age makes this option impractical for a majority of patients. As a result, coronary artery bypass graft (CABG) surgery is the optimal therapeutic approach and remains superior to medical therapy. Numerous controlled trials of coronary artery bypass grafting in patients with low left ventricular ejection fraction (LVEF), have shown that these are the patients that benefit most from revascularization, especially if symptoms of angina or ischemia are present. This benefit is not only for symptoms, but also on longevity. It is believed that the most important factor for successful surgical recovery may be the viability of revascularized myocardium.

• Study Type: Interventional
• Enrollment (Anticipated): 30
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: mahmoud Elkhawaga, master; Phone Number: 01002368945; Email: maelkhawaga8@gmail.com

Study Locations

• Egypt
  • Assiut, Egypt, 71111
    • Recruiting
    • Assiut university hospitals
    • Contact: Ahmed Elminshawy, professor; Phone Number: 01112743943; Email: aelminshawy@hotmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Angiographic indication for revascularization based upon symptoms of angina and/or objective evidence of myocardial ischemia.
2. Preoperative EF ≤ 40 %.
3. Preoperative myocardial viability (by cardiac MRI).
4. Willing and able to provide written informed consent and comply with study requirements.
5. Patient is willing to comply with all follow-up visits.

Exclusion Criteria:

1. Severe congestive heart failure (class III or IV according to NYHA, or pulmonary edema, cardiogenic shock) at the time of enrollment.
2. Prior surgery with the opening of pericardium.
3. Evidence of non-viable (scarred) myocardium.
4. Prior stroke (within 6 months)or more than 6 months if there are substantial neurological defects.
5. Acute ST-elevation MI within 72 hours prior to enrollment requiring revascularization.
6. Planned simultaneous surgical procedure unrelated to coronary revascularization (e.g. valve repair/replacement, aneurysmectomy, carotid endarterectomy or carotid stenting).
7. Significant leukopenia, neutropenia, thrombocytopenia, anemia, or known bleeding diathesis.
8. Intolerance or contraindication to aspirin or both clopidogrel and ticlopidine.
9. Extra-cardiac illness that is expected to limit survival to less than 5 years e.g. oxygen-dependent chronic obstructive pulmonary disease, active hepatitis or significant hepatic failure, severe renal disease.
10. EF ≤ 20 %.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: patients with low EF undergoing CABG; Chronic Unstable Angina patients with low ejection fraction and a viable myocardium will undergo surgical revascularization CABG	Procedure: CABG; surgical revascularization of stenosed coranary arteries using arterial and venous grafts.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
postoperative Ejection Fraction (EF)	The EF will be measured 3 months postoperative	3 months postoperative

Collaborators and Investigators

• Sponsor: Assiut University
• Investigators: Principal Investigator: Ahmed Elminshawy, professor, Assiut University

Study record dates

Study Major Dates

• Study Start (Actual): September 4, 2017
• Primary Completion (Anticipated): September 4, 2018
• Study Completion (Anticipated): March 1, 2019

Study Registration Dates

• First Submitted: September 4, 2017
• First Submitted That Met QC Criteria: September 6, 2017
• First Posted (Actual): September 8, 2017

Study Record Updates

• Last Update Posted (Actual): September 8, 2017
• Last Update Submitted That Met QC Criteria: September 6, 2017
• Last Verified: September 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Pain; Neurologic Manifestations; Chest Pain; Angina Pectoris; Angina, Unstable
• Other Study ID Numbers: CABGlowEF

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No